We’re proud to announce that Nanofacile has been selected as one of seven startups to join the first Canadian cohort of the Merck Digital Sciences Studio (MDSS), a major milestone in our mission to make RNA therapeutics faster, more efficient and accessible.
This international program, powered by Merck, in partnership with CQDM, Merck Global Health Innovation Fund, and Centech, brings together cutting edge startups shaping the future of digital health and biotechnology.
The announcement took place at Centech in Montreal, in the presence of Christopher Skeete, Quebec’s Minister for the Economy. His support highlights the province’s growing role as a strategic hub for health innovation on the global stage.
Why This Matters
The MDSS program provides selected startups with:
Expert mentorship from Merck’s global network
Strategic and financial support
Cloud credits and infrastructure resources
A global network of leaders in healthcare, tech, and venture capital
This is more than just a program. It’s a launchpad to sharpen our vision, pressure test our technology, and accelerate our impact.
What It Means for Nanofacile
Our selection into MDSS validates the urgency and potential of what we’re building: a plug and play platform for lipid nanoparticle (LNP) development that simplifies and accelerates RNA drug formulation and scale up.
As part of this cohort, we’ll be:
Working directly with industry veterans to push our platform further
Gaining visibility in key pharma and tech circles
Collaborating with other top-tier startups in digital health and biotech
This is a major step forward, not just for Nanofacile, but for the future of RNA delivery.
What’s Next
The journey is just getting started. With MDSS, we’re entering a new phase of growth. One defined by faster iteration, deeper collaboration, and global reach.
Stay tuned. The future of RNA delivery is being built right here, and we’re just getting started.